Invention Grant
- Patent Title: Method to determine responsiveness of cancer to epidermal growth factor receptor targeting treatments
-
Application No.: US15981514Application Date: 2018-05-16
-
Publication No.: US10669589B2Publication Date: 2020-06-02
- Inventor: Daphne Winifred Bell , Daniel A. Haber , Pasi Antero Janne , Bruce E. Johnson , Thomas J. Lynch , Matthew Meyerson , Juan Guillermo Paez , William R. Sellers , Jeffrey E. Settleman , Raffaella Sordella
- Applicant: The General Hospital Corporation , Dana-Farber Cancer Institute, Inc.
- Applicant Address: US MA Boston US MA Boston
- Assignee: The General Hospital Corporation,Dana-Farber Cancer Institute, Inc.
- Current Assignee: The General Hospital Corporation,Dana-Farber Cancer Institute, Inc.
- Current Assignee Address: US MA Boston US MA Boston
- Agency: Nixon Peabody LLP
- Agent David S. Resnick; Shayne Y. Huff
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; C12Q1/6886 ; C12Q1/48 ; G01N33/574 ; G01N33/74
Abstract:
Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.
Public/Granted literature
- US20180251860A1 METHOD TO DETERMINE RESPONSIVENESS OF CANCER TO EPIDERMAL GROWTH FACTOR RECEPTOR TARGETING TREATMENTS Public/Granted day:2018-09-06
Information query
